Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2018
Reporting Period: Fourth quarter and full year ended December 31, 2017.
This filing serves to announce the issuance of a press release regarding financial results for the period ended December 31, 2017. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K filing.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the fourth quarter and full year 2017 have been released.
Guidance, Outlook, and Risks
- Conference Call: The Company scheduled a conference call for February 28, 2018, at 9:00 a.m. Eastern Time to present the financial results. A live webcast was available on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: Investors are directed to Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, for a detailed discussion of risks.
- Legal Disclaimer: Information in Item 2.02 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release Dated February 27, 2018) for specific revenue, net income, and cash flow figures.
- Verify the details of the conference call and webcast archive on the Company's website (www.supernus.com).
- Consult the Form 10-K (filed March 16, 2017) and Form 10-Q (filed August 3, 2017) for comprehensive risk factors.
- Confirm that the financial results discussed are for the period ended December 31, 2017.